Triox Nano developed and patented a breakthrough disruptive technology for delivery of APIs to their target cells based on a patented S.M.A.R.T “Stimuli Multi Adjusted Responsive Technology” nano machinery technology. Our platform is based on a combination of MSNP + DNA molecular machines or other smart caps which enable preprogramming of the capping mechanism to react to a combination of variables.
We chose to start with an indication called TNBC(Triple Negative Breast Cancer) which has a great unmet need
In vitro testing show up to 50 times greater efficacy in TNBC compared to Doxil(liposomal doxorubicin) and enter healthy cells 3 times less.
In Vivo testing with over 200 animals show a 10-20 times stronger histologic result per molecule compared to Liposomal doxorubicin (Doxil, Caelyx) allowing us to give 25% of the Doxil dose and get up to 4 time better gamma-h2ax results.
We had just received an approval of our PCT in Europe. WO 2014087410 A1 ABSTRACT Recognition-release nanoporous substrate comprising active agents, methods of their preparation and uses.
No other company can utilize this synergistic combination of DNA MM and MSNP.
Our IP is very strong as we invented this field of science our approved PCT patent claims that any porous particle capped by at least one nucleic acid sequence and the agent is released by a triggered reaction of said capping sequence with at least one analyte (biomarker) thereby allowing said capping to be cleaved from said pore.
